Net profit surged 40.5% year-over-year to W1,369bn in 1H FY24, driven by health market growth and investment gains. CSM balance rose to W12.7tn, with robust new business in health products. Dividend yield reached 5.1% in FY23.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.